



doximity

# INVESTOR PRESENTATION

FALL 2025

# LEGAL DISCLAIMER

This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial and operating metrics, capital expenditures, plans for future operations, competitive position, technological capabilities, and strategic relationships, general business conditions and the assumptions underlying those statements.

Any forward-looking statements contained in this presentation and associated commentary are based upon Doximity's historical performance and its plans, estimates and expectations as of the dates noted in this presentation, and are not a representation that such plans, estimates, or expectations have been or will be achieved. These forward-looking statements represent Doximity's expectations as of the dates noted in this presentation. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Subsequent events may cause these expectations to change, and Doximity disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including, but not limited to, those related to our business and financial performance, our ability to attract and retain customers, our ability to develop new products and services and enhance existing products and services, our ability to respond rapidly to emerging technology trends, our ability to execute on our business strategy, our ability to compete effectively and our ability to manage growth.

Additional risks and uncertainties that could affect Doximity's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's filings with the Securities and Exchange Commission on Form 10-K and subsequent Form 10-Qs. These materials are available on our investor relations website at [investors.doximity.com](https://investors.doximity.com) under the Financials section and on the SEC's website at [sec.gov](https://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Doximity makes with the SEC from time to time. In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and associated commentary may include certain non-GAAP financial measures (including on a forward-looking basis) such as Adjusted EBITDA and Free Cash Flow. Definitions and reconciliations of non-GAAP measures to their most directly comparable GAAP counterparts are available in our most recent Form 10-K or 10-Q on the company's investor relations website at [investors.doximity.com](https://investors.doximity.com).

# THE DIGITAL PLATFORM FOR DOCTORS

Leading Network

80%+

of all U.S.  
Physicians<sup>1</sup>

Blue Chip Clients

20/20

Top Hospitals  
and Health Systems  
Top Pharmaceutical  
Manufacturers<sup>3</sup>

>650K

Workflow Unique  
Active Providers<sup>2</sup>

118%

Net Revenue  
Retention Rate<sup>4</sup>

1. As of 9/30/25.

2. For fiscal quarter ending 9/30/25.

3. Top 20 Pharmaceutical Manufacturers based on data from Evaluate, Top 20 hospitals based on U.S. News & World Report's Best Hospitals U.S. News Best Hospitals 2024-2025 Honor Roll.

4. For the trailing twelve month (TTM) period ending 9/30/25. Refer to appendix for definitions and non-GAAP reconciliations.

# GLARING DAY-TO-DAY INEFFICIENCIES

70%

of US HC communication still sent via fax<sup>1</sup>

75%

of physicians attribute **burnout** to electronic health record (EHR) inefficiencies<sup>2</sup>


1. Konica Minolta, "New Facts About Fax in Healthcare," 2023.

2. Tajirian et al., "The Influence of Electronic Health Record Use on Physician Burnout," J Med Internet Res, 2020.



# BRINGING TECH TO MEDICINE

Inspired by enterprise tech



*Note: These are not customers or partners, these are illustrative examples of premier enterprise tech solutions in their respective markets.*



Purpose-built for healthcare



4.8 out of 5, 185K+ Ratings & Reviews<sup>1</sup>




“This app has changed my professional life.”


1. As of November, 2025.

# PURPOSE BUILT FOR HEALTHCARE




## Professional Network



## Newsfeed




## Workflow




# A COMPLETE AI SUITE FOR CLINICIANS


A free, HIPAA-compliant suite of AI tools that is private to each clinician



Scribe




Write



Answer

# STRONG ENGAGEMENT




News

>1M QAU<sup>1</sup>



Workflow

>650K QAU<sup>1</sup>




AI

AI QAU<sup>1</sup> up >50% Q/Q

1. QAU are unique quarterly active prescribers (MD/DO/NP/PA/Pharmacist/Med Student/CRNA)


# ENGAGEMENT THROUGHOUT THE DAY

1



# OUR COMMERCIAL SOLUTIONS

## Marketing




### Educate on Latest News & Treatments

*Relevance and personalization drive Rx's & Referrals*

1. Based on "Best in KLAS" Telehealth Video Conferencing Platform 2025

## Hiring



### Uncover Passive Candidates

*Find specialized talent*

## Enterprise Workflow




### Reduce No-Shows & Leakage

*#1 "Best in KLAS" Telehealth Video Conferencing  
Hundreds of thousands of on-call schedules  
AI driven clinical correspondence*


# MARKETING SOLUTIONS

Largest Revenue Driver: Marketing Solutions



## Leading Network

>73% of healthcare spend  
is decided by Doctors<sup>1</sup>



## Subscription Pricing Model

1. Audience (e.g. specialty)
2. Number of audience members
3. Type and number of modules



17:1 ROI<sup>2</sup>  
LexisNexis



> 11:1 ROI<sup>3</sup>  
IQVIA

1. Center for Medicare & Medicaid Services, including categories of hospital care, physician & clinical services, retail prescription drugs, nursing care facilities & continuing care retirement communities, home health care, & durable medical equipment.


2. Our ROI studies are conducted using data from third party provider LexisNexis Risk Solutions for our health system customers. Median ROI as measured by third party claims data analysis of shared patient lift from new referring providers. As of September 2022.

3. Actual results vary based on therapy area, product price, product maturity, and the number of months over which the ROI was measured. As of March 2024.


# LAND & EXPAND SALES MOTION

1

Land Initial Brands or Service Lines




Pharmaceutical Manufacturer




Health System

2

Expand to Add'l Brands or Service Lines




Pharmaceutical Manufacturer




Health System

3

Expand Number  
& Type of  
Modules Utilized




Pharmaceutical Manufacturer




Health System

# CORE NEWSFEED MODULES


We create  
customized  
packages for  
customers



Long Form



Video




Short Form

# WORKFLOW MODULES




Point of Care



Formulary

# LARGE & GROWING TOTAL ADDRESSABLE MARKET




1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacturers to Doctors. Source: IQVIA 2019 US ChannelDynamics and Kantar Media Intelligence, US Healthcare Ad Spend

2. Health System Marketing and Staffing TAM represents Hospital Marketing Spend, Revenue Opportunity from Locum Tenens solutions and Permanent Staffing solutions. Source: BIA Advisory Services, GVR, Kaiser Family Foundation and the AAPPR In-House Physician and Provider Recruitment benchmarking

3. Telehealth TAM represents revenue opportunity from Telehealth sales to care locations and individuals. Source: IBISWorld


# PHARMA BRAND OPPORTUNITY

Our Penetration into  
>\$100M US Mega Brands<sup>1</sup>




● % Signed ○ % Not Signed

Our Penetration into  
<\$100M US Mid Tier Brands<sup>2</sup>



● % Signed ○ % Not Signed

Estimated Share of HCP Marketing  
Budget (all >\$1m Brands)<sup>3</sup>



○ 1.) No Revenue ● 2.) <5% ● 3.) 5% - 20% ● 4.) 20% - 50% ● >50%

1. As of March 31, 2025. # of brands with \$100m+ in US sales (based on data from Evaluate Pharma) where Doximity has revenue.

2. As of March 31, 2025. # of brands between \$1m to \$100m in US sales (based on data from Evaluate Pharma) where Doximity has revenue.

3. As of March 31, 2025. Estimated Doximity Share of HCP Marketing Budgets is calculated by assuming a certain percent of a brand's US Sales is spent on HCP marketing. We then take Doximity's revenue for that brand and divide it by our estimate of its HCP marketing budget. This is looking at Doximity Share of HCP Marketing Budgets for the cohort of brands with \$1m+ in US Sales.

# Q2 KEY METRICS

## LAND

Number of Customers w/ \$500K+ of Revenue<sup>1</sup>

121 \$500K+  
+ 16% y/y

&

## EXPAND



Net Revenue Retention<sup>2</sup>

118%  
Total Company

Top 20  
Customers  
118%

1. Refer to appendix for the definition of customers with trailing 12-month subscription revenue greater than \$500,000.  
2. Refer to appendix for the definition of Net Revenue Retention.

# ATTRACTIVE REVENUE GROWTH & MARGIN PROFILE



# FOUNDER-LED, MISSION DRIVEN



Jeff Tangney  
CEO & Co-Founder



Anna Bryson  
CFO



Lisa Greenbaum  
CCO



Jey Balachandran  
CTO



Amit Phull, MD  
Chief Clinical Experience Officer



Ben Greenberg  
SVP Commercial Products



Joel Davis  
SVP Product



John Vaughn  
General Counsel

856  
EMPLOYEES<sup>1</sup>

1/3+  
IN R&D<sup>1</sup>

<sup>1</sup> As of September 30, 2025.

# COMPANY HIGHLIGHTS

- 1 Leading digital platform for doctors
- 2 Powerful network effects
- 3 Sustainable revenue growth & profitability
- 4 Veteran vertical team
- 5 Massive near-term market opportunity fueled by shift to digital

# APPENDIX: NON-GAAP FINANCIAL MEASURES

To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

**Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share:** We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, impairment charge, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.

**Adjusted EBITDA and adjusted EBITDA margin:** We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, impairment charge, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

**Free cash flow:** We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

## Key Business Metrics

**Net revenue retention rate:** Net revenue retention rate is calculated by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.

**Customers with trailing 12-month subscription revenue greater than \$500,000:** The number of customers with TTM subscription revenue greater than \$500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than \$500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

# APPENDIX: ADJUSTED EBITDA & MARGIN NON-GAAP RECONCILIATION

|                                                                     | Year Ended March 31, |           |           |           |           | TTM       |
|---------------------------------------------------------------------|----------------------|-----------|-----------|-----------|-----------|-----------|
|                                                                     | 2021                 | 2022      | 2023      | 2024      | 2025      | Q2 FY26   |
|                                                                     | (in thousands)       |           |           |           |           |           |
| Net Income                                                          | \$50,210             | \$154,783 | \$112,818 | \$147,582 | \$223,185 | \$253,034 |
| Adjustments:                                                        |                      |           |           |           |           |           |
| Acquisition and other related expenses                              | 496                  | 254       | 30        | —         | —         | 1,616     |
| Stock-based compensation                                            | 7,252                | 31,442    | 47,834    | 47,430    | 72,386    | 88,768    |
| Depreciation and amortization                                       | 3,702                | 5,040     | 10,283    | 10,265    | 10,659    | 11,746    |
| Provision for (benefit from) income taxes                           | 7,559                | (40,778)  | 20,338    | 37,620    | 40,389    | 32,286    |
| Impairment charge                                                   | —                    | —         | —         | 7,936     | 2,304     | —         |
| Change in fair value of contingent earn-out consideration liability | —                    | —         | 728       | 951       | 680       | 517       |
| Legal expenses                                                      | —                    | —         | —         | —         | —         | 2,927     |
| Other income, net                                                   | (4,466)              | (469)     | (8,048)   | (21,324)  | (35,774)  | (38,516)  |
| Adjusted EBITDA                                                     | \$64,753             | \$150,272 | \$183,983 | \$230,460 | \$313,829 | \$352,378 |
| Revenue                                                             | \$206,897            | \$343,548 | \$419,052 | \$475,422 | \$570,399 | \$621,329 |
| Adjusted EBITDA Margin                                              | 31%                  | 44%       | 44%       | 48%       | 55%       | 57%       |